Surgery: Future directions in multimodality therapy for NSCLC
- PMID: 20029443
- DOI: 10.1038/nrclinonc.2009.174
Surgery: Future directions in multimodality therapy for NSCLC
Abstract
Patients with stage III non-small-cell lung cancer (nSclc) comprise a heterogeneous population; the role of surgical resection in this setting has been controversial. Albain and colleagues recently demonstrated that trimodality therapy with lobectomy had clinical benefit for patients with pathologic nodal N2 stage III nSclc. we discuss the trial and its implications for future lung cancer therapy.
Comment on
-
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.Lancet. 2009 Aug 1;374(9687):379-86. doi: 10.1016/S0140-6736(09)60737-6. Epub 2009 Jul 24. Lancet. 2009. PMID: 19632716 Free PMC article. Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
